<DOC>
	<DOCNO>NCT02029430</DOCNO>
	<brief_summary>This pilot study determine efficacy , kinetics safety aldoxorubicin HIV positive subject Kaposi 's sarcoma .</brief_summary>
	<brief_title>A Study Investigate ALDOXORUBICIN HIV-infected Subjects With Kaposi 's Sarcoma</brief_title>
	<detailed_description>This open-label pilot phase 2 study investigate efficacy , safety , intratumoral kinetics aldoxorubicin HIV-Infected patient Kaposi 's sarcoma .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>HIV Seropositivity</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Age ≥18 year age ; male female . 2 . HIV ( confirm ELISA western blot ) histologically confirm KS . 3 . Willing undergo serial tumor biopsy . 4 . Capable provide informed consent comply trial procedure . 5 . KPS ≥70 ( Appendix B ) 6 . Easter Cooperative Oncology Group ( ECOG ) PS 02 . 7 . Life expectancy ≥ 8 week . 8 . Measurable ( accessible site radiographic ) tumor lesion accord ACTG TIS criterion . 9 . Women must able become pregnant ( e.g . postmenopausal least 1 year , surgically sterile , practice adequate birth control method ) duration study . ( Adequate contraception include : oral contraception , implanted contraception , intrauterine device implant least 3 month , barrier method conjunction spermicide . ) 10 . Women child bear potential must negative serum urine pregnancy test Screening Visit nonlactating . 11 . Geographic accessibility site . 1 . Prior exposure anthracycline . 2 . Surgery and/or radiation treatment &lt; 4 week prior Randomization . 3 . Exposure investigational agent within 30 day Randomization . 4 . History malignancy ( except cure basal cell carcinoma , superficial bladder cancer carcinoma situ cervix ) unless document free cancer ≥3 year . 5 . Laboratory value : Screening serum creatinine &gt; 1.5 × upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) &gt; 2.5 × ULN , total bilirubin &gt; 1.5 × ULN , absolute neutrophil count ( ANC ) &lt; 1,500/mm3 , platelet concentration &lt; 75,000/mm3 , absolute lymphocyte count &lt; 1000/mm3 , hematocrit level &lt; 25 % female &lt; 27 % male , serum albumin ≤2.5 g/dL . 6 . Evidence central nervous system ( CNS ) hemorrhage National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) version 4.0 ( publish 28 May 2009 ) grade 2 great baseline MRI . 7 . Clinically evident congestive heart failure ( CHF ) &gt; class II New York Heart Association ( NYHA ) guideline . 8 . Current , serious , clinically significant cardiac arrhythmia , define existence absolute arrhythmia ventricular arrhythmia classify Lown III , IV V. 9 . History sign active coronary artery disease without angina pectoris . 10 . Serious myocardial dysfunction define ultrasounddetermined absolute leave ventricular ejection fraction ( LVEF ) &lt; 45 % predict institutional normal value . 11 . Active , clinically significant serious infection require treatment antibacterial , antiviral ( antiretroviral therapy ) , antifungal therapy . 12 . Major surgery within 4 week prior Randomization . 13 . Any condition might interfere subject 's participation study evaluation study result . 14 . Any condition unstable could jeopardize subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HIV +</keyword>
	<keyword>HIV positive</keyword>
	<keyword>AIDS</keyword>
	<keyword>Kaposi 's sarcoma</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>tumor</keyword>
	<keyword>cancer</keyword>
</DOC>